CDK9-IN-2 is a special cyclin-dependent kinase 9 ( CDK9 ) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC 50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.In VitroCDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic (PD) marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment and is further reduced after 16 hour exposure to CDK9-IN-2 (500 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid. Specification: 0.99 Molecular Formula: C23H25ClFN5 Molecular Weight: 425.93 PubChem CID: 49855228 Isomeric SMILES: C1CC(CCC1N)NC2=NC=C(C(=C2)C3=NC(=CC=C3)NCC4=CC(=CC=C4)F)Cl
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- C651682-5mg
- CAS:
- 1263369-28-3
- Product Size:
- 5mg
